382150 Stock Chart & Stats
₩2945.00
₩215.00(7.88%)
―
--
Day’s Range― - ―
52-Week Range₩2,235.00 - ₩14,490.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)44.12K
Market Cap
₩38.42B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.23
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding13,046,354
10 Day Avg. Volume24,731
30 Day Avg. Volume44,119
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
382150 FAQ
What was Oncocross Co., Ltd.’s price range in the past 12 months?
Oncocross Co., Ltd. lowest stock price was ₩2235.00 and its highest was ₩14490.00 in the past 12 months.
What is Oncocross Co., Ltd.’s market cap?
Oncocross Co., Ltd.’s market cap is ₩38.42B.
When is Oncocross Co., Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Oncocross Co., Ltd.’s earnings last quarter?
Oncocross Co., Ltd. released its earnings results on May 14, 2026. The company reported -₩216.842 earnings per share for the quarter, missing the consensus estimate of N/A by -₩216.842.
Is Oncocross Co., Ltd. overvalued?
According to Wall Street analysts Oncocross Co., Ltd.’s price is currently Undervalued.
Does Oncocross Co., Ltd. pay dividends?
Oncocross Co., Ltd. does not currently pay dividends.
What is Oncocross Co., Ltd.’s EPS estimate?
Oncocross Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncocross Co., Ltd. have?
Oncocross Co., Ltd. has 13,046,354 shares outstanding.
What happened to Oncocross Co., Ltd.’s price movement after its last earnings report?
Oncocross Co., Ltd. reported an EPS of -₩216.842 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.421%.
Which hedge fund is a major shareholder of Oncocross Co., Ltd.?
Currently, no hedge funds are holding shares in KR:382150
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Linkgenesis Co. Ltd.
―
SYNTEKABIO, INC.
―
Gencurix, Inc.
―
Aligned Genetics, Inc.
―
Carelabs Co., Ltd.
―